Cue Biopharma (CUE) awards 21,800 time-vested RSUs to director Garzone

Rhea-AI Filing Summary

Garzone Pamela reported acquisition or exercise transactions in this Form 4 filing.

Cue Biopharma, Inc. reported that director Pamela Garzone received a grant of 21,800 shares of Common Stock in the form of restricted stock units. One-third of the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, contingent on her continued service with the company. Following this equity award, she holds 21,800 shares directly.

Insights

Equity Compensation Analyst

Director received 21,800 RSUs vesting over three years as routine equity compensation.

Director Pamela Garzone was granted 21,800 restricted stock units (RSUs) of Cue Biopharma Common Stock at a stated transaction price of $0.0000 per share, reflecting a non-cash equity award rather than an open-market purchase. This aligns her compensation partly with shareholder outcomes.

According to the vesting schedule, one-third of the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, conditioned on her continued service. This time-based vesting encourages longer-term board service and alignment with the company’s multi-year performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Garzone Pamela

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	21,800	$0.00	--

Holdings After Transaction: Common Stock — 21,800 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs Granted: 21,800 shares Transaction Price per Share: $0.0000 Shares After Transaction: 21,800 shares +3 more

6 metrics

RSUs Granted 21,800 shares Restricted stock units of Common Stock granted to director Pamela Garzone

Transaction Price per Share $0.0000 Stated transaction price for the RSU grant, indicating non-cash compensation

Shares After Transaction 21,800 shares Total Common Stock held directly by Pamela Garzone following the award

First Vesting Date July 9, 2027 One-third of RSUs vest on this date, subject to continued service

Second Vesting Date July 9, 2028 Second one-third of RSUs vest on this date, subject to continued service

Third Vesting Date July 9, 2029 Final one-third of RSUs vest on this date, subject to continued service

Key Terms

restricted stock units, RSUs, vesting, continued service

4 terms

restricted stock units financial

"Represents the grant of restricted stock units ("RSUs")."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs financial

"Represents the grant of restricted stock units ("RSUs")."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

vesting financial

"One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continued service financial

"subject to the reporting person's continued service with the issuer through each such vest date."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 07:38 PM Accepted by SEC EDGAR 07/10/2026 - 07:37 PM Learn about SEC filing dates

FAQ

What equity award did Pamela Garzone receive from Cue Biopharma (CUE)?

Director Pamela Garzone received a grant of 21,800 restricted stock units (RSUs) of Cue Biopharma Common Stock. The award is a non-cash equity grant recorded at a transaction price of $0.0000 per share.

How do the 21,800 RSUs granted to Pamela Garzone at Cue Biopharma (CUE) vest?

The 21,800 RSUs vest in three equal installments. One-third vests on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to her continued service with Cue Biopharma.

Is Pamela Garzone’s Cue Biopharma (CUE) RSU grant an open-market stock purchase?

No. The filing describes a grant/award acquisition of 21,800 RSUs with a transaction price of $0.0000 per share, indicating compensation-based equity, not an open-market purchase.

What are Pamela Garzone’s Cue Biopharma (CUE) share holdings after this RSU grant?

After the RSU grant, the filing shows total shares following the transaction of 21,800, held as direct ownership. These represent her reported Common Stock position post-award.

What conditions apply to vesting of the Cue Biopharma (CUE) RSUs granted to Pamela Garzone?

Vesting of the 21,800 RSUs is conditioned on continued service with Cue Biopharma. One-third of the units vest on each annual anniversary date from 2027 through 2029, provided she remains in service.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Garzone Pamela

(Last) (First) (Middle)

C/O CUE BIOPHARMA, INC.

40 GUEST STREET

(Street)

BOSTON MASSACHUSETTS 02135

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cue Biopharma, Inc. [ CUE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		A		21,800(1)	A	$0	21,800	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the grant of restricted stock units ("RSUs"). One-third of the shares subject to the RSUs vest on each of July 9, 2027, July 9, 2028, and July 9, 2029, subject to the reporting person's continued service with the issuer through each such vest date.

	/s/ Michael Meluzio, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)